Home » Archive

News

News, Syndication, Xconomy »

Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies

Posted by sandiegobiotech May 16th, 2012 .
No Comments

[Updated: 11 am PT, 6/5/12] One of the big dreams in biotech over the past 35 years has been to make drugs that work like “smart bombs” by destroying tumors while minimizing collateral damage….

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

ASCO Preview: Eight Cancer Drugs to Watch at the Big Show

Posted by sandiegobiotech May 14th, 2012 .
No Comments

The pistons of the biggest publicity engine in cancer R&D will start firing this week. It’s time to behold the annual rite of the American Society of Clinical Oncology (ASCO) meeting, the biggest…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

SD Life Sciences Roundup: Celladon, Vertex, MediciNova, & More

Posted by sandiegobiotech May 10th, 2012 .
No Comments

Massachusetts’ Vertex and San Diego’s Celladon are advancing some promising gene therapy treatments. Here’s our roundup of life sciences news over the past week. —San Diego’s Celladon, which is…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Cytori Provides Business Update; Reports First Quarter Results

Posted by Mary Canady May 9th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 9, 2012) – During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline, grew the commercial business, and strengthened operational and financial performance…

More...

News, Syndication, Xconomy »

A 10-Point Plan to Stimulate Biotech & the Economy as a Whole

Posted by sandiegobiotech May 9th, 2012 .
No Comments

AN OPEN LETTER TO PRESIDENT OBAMA Dear President Obama: As you and the rest of our nation’s leadership grapple with the momentous questions of restoring our collective financial stability and…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s MediciNova Nears Turning Point with Lead Drug for Asthma

Posted by sandiegobiotech May 8th, 2012 .
No Comments

[Corrected 5/7/12, 5:10 pm. See below.] When Yuichi Iwaki started MediciNova in 2000, he says many mid-size pharmaceutical companies in Japan had concluded it was just too difficult to conduct their…

[[Click headline to continue reading.]]

More...

News, Syndication, Xconomy »

San Diego’s Celladon Extends Round to $53M, Opens European Office

Posted by sandiegobiotech May 8th, 2012 .
No Comments

San Diego-based Celladon, which raised $43 million in February to advance development of a gene therapy treatment for heart disease, has extended the round with an additional $10 million, according…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Bio-Matrix Scientific Group, Inc. Hires President for Its Regen BioPharma Subsidiary

Posted by Mary Canady May 8th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 8, 2012) – Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today that J. Christopher Mizer has joined the Company as President and Chief Operating Officer of its Regen BioPharma subsidiar…

More...

News, Syndication, Xconomy »

First Comes The $1,000 genome, Then Comes The $10,000 Analysis

Posted by sandiegobiotech May 8th, 2012 .
No Comments

While everyone in the in the world of sequencing has heard this cynical joke, as an industry, the joke is about to be on us. We have focused our time, energy and investment on the ability to sequence…

[[Click headline to continue reading.]]

More...

Marketwire, News, Syndication »

Ardea Biosciences Announces First Quarter 2012 Financial Results

Posted by Mary Canady May 7th, 2012 .
No Comments

SAN DIEGO, CA–(Marketwire – May 7, 2012) – Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced first quarter 2012 financial…

More...